publication date: Oct. 10, 2014

 

Past Coverage of the NCI Bypass Budget

NIH to Review Intramural Program

NCI’s Intramural Spending is 17 Percent, Higher than 11.1 Percent NIH-Wide Level

March 7, 2014  –  NIH has launched a systematic examination of its intramural program, which accounts for 11.1 percent of its $30 billion budget.

The program was last examined in 1993, pursuant to a mandate from the House Appropriations Committee.

That examination was written by a panel co-chaired by Paul Marks, then president of Memorial Sloan-Kettering Cancer Center and Gail Cassell, then chair of the University of Alabama Department Microbiology.

NIH Director: NCI’s Special Authorities
“More Of A Negative Than A Positive.”

ASCO: NCI Authorities Still Important.

DeVita: “The War On Cancer Is Dead.”

June 11, 2010  –  Special authorities given to NCI under the National Cancer Act of 1971 have been “more of a negative than a positive,” said NIH Director Francis Collins.

In an interview with the journal Science, Collins reignited a controversy that predates the federal government’s “war on cancer” and brings into question survival of NCI’s unique features.

Harold Freeman to Direct NCI Center to Reduce Cancer Health Disparities

Sept. 15, 2000  –  Responding to criticism from patient advocates and researchers, NCI has established a center for studying disparities in the cancer burden experienced by some populations.

According to a draft of the NCI Bypass Budget for fiscal 2002, the Institute would like to spend $2 million for operations and $42.6 million for research projects administered through the new Center to Reduce Cancer Health Disparities.

Bypass Budget Omits Needless Words: Faster Progress to Cost $421 Million More

March 29, 1996  –  As symbols go, the NCI Bypass Budget warrants respect: the document gives the NCI Director a chance to give the US President a summary of opportunities in cancer research.

The document has never been an easy read. It has challenged the reader to sift through 500-plus pages of heavy narrative laden with the jargons of science and bureaucracy.

Copyright (c) 2020 The Cancer Letter Inc.